Cargando…

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144

Non-neutralizing IgG to the V1V2 loop of HIV-1 gp120 correlates with a decreased risk of HIV-1 infection but the mechanism of protection remains unknown. This V1V2 IgG correlate was identified in RV144 Thai trial vaccine recipients, who were primed with a canarypox vector expressing membrane-bound g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Lautaro G., Martinez, David R., deCamp, Allan C., Pinter, Abraham, Berman, Phillip W., Francis, Donald, Sinangil, Faruk, Lee, Carter, Greene, Kelli, Gao, Hongmei, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, O’Connell, Robert J., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Gilbert, Peter, Montefiori, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498072/ https://www.ncbi.nlm.nih.gov/pubmed/28678869 http://dx.doi.org/10.1371/journal.pone.0180720

Ejemplares similares

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
por: Fischinger, Stephanie, et al.
Publicado: (2020)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
por: Nicely, Nathan I., et al.
Publicado: (2015)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
por: Edlefsen, Paul T., et al.
Publicado: (2015)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
por: Lewitus, Eric, et al.
Publicado: (2021)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants
por: Dommaraju, Kalpana, et al.
Publicado: (2014)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
por: McLellan, JS, et al.
Publicado: (2012)

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection
por: Wang, Yufei, et al.
Publicado: (2017)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
por: Easterhoff, David, et al.
Publicado: (2017)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
por: Shubin, Zhanna, et al.
Publicado: (2023)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor
por: Peachman, Kristina K., et al.
Publicado: (2015)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

Aggregate complexes of HIV-1 induced by multimeric antibodies
por: Stieh, Daniel J, et al.
Publicado: (2014)

RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2020)

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
por: Zolla-Pazner, Susan, et al.
Publicado: (2014)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2021)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
por: Gilbert, Peter B., et al.
Publicado: (2017)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
por: Zolla-Pazner, Susan, et al.
Publicado: (2014)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
por: Pitisuttithum, Punnee, et al.
Publicado: (2013)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
por: Yates, Nicole L., et al.
Publicado: (2018)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection
por: Auclair, Sarah, et al.
Publicado: (2018)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
por: Lemke, Melissa M., et al.
Publicado: (2021)

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
por: Karasavvas, Nicos, et al.
Publicado: (2015)

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
por: Janes, Holly, et al.
Publicado: (2015)

A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination
por: Lemke, Melissa M., et al.
Publicado: (2022)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
por: Karasavvas, N, et al.
Publicado: (2012)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
por: Hertz, T, et al.
Publicado: (2012)

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis
por: Wills, Saintedym, et al.
Publicado: (2018)

Molecular epidemiology of the protective RV144 V2 loop epitope
por: Cardozo, T
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hoiucr160pvg6f2ehj0ohlntts